Cargando…

Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials

BACKGROUND: A previous study had identified 45 items assessing the impact of atopic dermatitis (AD) on the whole family. From these it was intended to develop two separate scales, one assessing impact on carers and the other determining the effect on the child. METHODS: The 45 items were included in...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenna, Stephen P, Doward, Lynda C, Meads, David M, Tennant, Alan, Lawton, Gemma, Grueger, Jens
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994672/
https://www.ncbi.nlm.nih.gov/pubmed/17662129
http://dx.doi.org/10.1186/1477-7525-5-45
_version_ 1782135488975470592
author McKenna, Stephen P
Doward, Lynda C
Meads, David M
Tennant, Alan
Lawton, Gemma
Grueger, Jens
author_facet McKenna, Stephen P
Doward, Lynda C
Meads, David M
Tennant, Alan
Lawton, Gemma
Grueger, Jens
author_sort McKenna, Stephen P
collection PubMed
description BACKGROUND: A previous study had identified 45 items assessing the impact of atopic dermatitis (AD) on the whole family. From these it was intended to develop two separate scales, one assessing impact on carers and the other determining the effect on the child. METHODS: The 45 items were included in three clinical trials designed to test the efficacy of a new topical treatment (pimecrolimus, Elidel cream 1%) in the treatment of AD in infants and children and in validation studies in the UK, US, Germany, France and the Netherlands. Rasch analyses were undertaken to determine whether an internationally valid, unidimensional scale could be developed that would inform on the direct impact of AD on the child. RESULTS: Rasch analyses applied to the data from the trials indicated that the draft measure consisted of two scales, one assessing the QoL of the carer and the other (consisting of 12 items) measuring the impact of AD on the child. Three of the 12 potential items failed to fit the measurement model in Europe and five in the US. In addition, four items exhibiting differential item functioning (DIF) by country were identified. After removing the misfitting items and controlling for DIF it was possible to derive a scale; The Childhood Impact of Atopic Dermatitis (CIAD) with good item fit for each trial analysis. Analysis of the validation data from each of the different countries confirmed that the CIAD had adequate internal consistency, reproducibility and construct validity. The CIAD demonstrated the benefits of treatment with Elidel over placebo in the European trial. A similar (non-significant) trend was found for the US trials. CONCLUSION: The study represents a novel method of dealing with the problem of DIF associated with different cultures. Such problems are likely to arise in any multinational study involving patient-reported outcome measures, as items in the scales are likely to be valued differently in different cultures. However, where all items in a scale fit both a single theoretical construct and the Rasch measurement model, it is feasible to conceive of outcome measures with a different set of items in each language.
format Text
id pubmed-1994672
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19946722007-09-27 Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials McKenna, Stephen P Doward, Lynda C Meads, David M Tennant, Alan Lawton, Gemma Grueger, Jens Health Qual Life Outcomes Research BACKGROUND: A previous study had identified 45 items assessing the impact of atopic dermatitis (AD) on the whole family. From these it was intended to develop two separate scales, one assessing impact on carers and the other determining the effect on the child. METHODS: The 45 items were included in three clinical trials designed to test the efficacy of a new topical treatment (pimecrolimus, Elidel cream 1%) in the treatment of AD in infants and children and in validation studies in the UK, US, Germany, France and the Netherlands. Rasch analyses were undertaken to determine whether an internationally valid, unidimensional scale could be developed that would inform on the direct impact of AD on the child. RESULTS: Rasch analyses applied to the data from the trials indicated that the draft measure consisted of two scales, one assessing the QoL of the carer and the other (consisting of 12 items) measuring the impact of AD on the child. Three of the 12 potential items failed to fit the measurement model in Europe and five in the US. In addition, four items exhibiting differential item functioning (DIF) by country were identified. After removing the misfitting items and controlling for DIF it was possible to derive a scale; The Childhood Impact of Atopic Dermatitis (CIAD) with good item fit for each trial analysis. Analysis of the validation data from each of the different countries confirmed that the CIAD had adequate internal consistency, reproducibility and construct validity. The CIAD demonstrated the benefits of treatment with Elidel over placebo in the European trial. A similar (non-significant) trend was found for the US trials. CONCLUSION: The study represents a novel method of dealing with the problem of DIF associated with different cultures. Such problems are likely to arise in any multinational study involving patient-reported outcome measures, as items in the scales are likely to be valued differently in different cultures. However, where all items in a scale fit both a single theoretical construct and the Rasch measurement model, it is feasible to conceive of outcome measures with a different set of items in each language. BioMed Central 2007-07-27 /pmc/articles/PMC1994672/ /pubmed/17662129 http://dx.doi.org/10.1186/1477-7525-5-45 Text en Copyright © 2007 McKenna et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
McKenna, Stephen P
Doward, Lynda C
Meads, David M
Tennant, Alan
Lawton, Gemma
Grueger, Jens
Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title_full Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title_fullStr Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title_full_unstemmed Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title_short Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials
title_sort quality of life in infants and children with atopic dermatitis: addressing issues of differential item functioning across countries in multinational clinical trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994672/
https://www.ncbi.nlm.nih.gov/pubmed/17662129
http://dx.doi.org/10.1186/1477-7525-5-45
work_keys_str_mv AT mckennastephenp qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials
AT dowardlyndac qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials
AT meadsdavidm qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials
AT tennantalan qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials
AT lawtongemma qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials
AT gruegerjens qualityoflifeininfantsandchildrenwithatopicdermatitisaddressingissuesofdifferentialitemfunctioningacrosscountriesinmultinationalclinicaltrials